Medications

What Is Mounjaro? Tirzepatide Guide for Weight Loss & Diabetes

GLP-1 Companion · 8 min read

Mounjaro (tirzepatide) burst onto the diabetes and weight loss scene as a groundbreaking medication that targets two incretin hormones simultaneously. Manufactured by Eli Lilly, it became one of the most talked-about treatments in modern medicine thanks to unprecedented clinical trial results showing significant weight reduction and blood sugar control.

What Is Mounjaro and How Does It Work?

Mounjaro is the brand name for tirzepatide, an injectable prescription medication that activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual-agonist mechanism sets it apart from older GLP-1-only medications like semaglutide. By engaging both pathways, tirzepatide amplifies the body's natural signals for insulin secretion, appetite suppression, and metabolic regulation.

The Dual GLP-1/GIP Mechanism Explained

GLP-1 and GIP are incretin hormones released by the gut after eating. GLP-1 slows gastric emptying, promotes insulin release, suppresses glucagon, and reduces appetite. GIP enhances insulin sensitivity and may play a role in fat metabolism. By activating both receptors, Mounjaro delivers complementary metabolic benefits that neither pathway achieves alone, which may explain its superior efficacy in clinical trials.

FDA Approval and Indications

The FDA approved Mounjaro in May 2022 for the treatment of type 2 diabetes in adults, as an adjunct to diet and exercise. It is not currently FDA-approved for weight loss under the Mounjaro brand name; however, tirzepatide received a separate weight-loss approval under the brand name Zepbound in November 2023. Many physicians prescribe Mounjaro off-label for weight management in patients who do not have diabetes.

Dosing: From 2.5 mg to 15 mg

Mounjaro is administered as a once-weekly subcutaneous injection using a prefilled, single-dose pen. The dosing schedule follows a gradual escalation to minimize gastrointestinal side effects and allow the body to adapt.

1. Weeks 1–4: 2.5 mg once weekly (starting dose, primarily for tolerability)
2. Weeks 5–8: 5 mg once weekly (first therapeutic dose)
3. Weeks 9–12: 7.5 mg once weekly (if additional efficacy is needed)
4. Weeks 13–16: 10 mg once weekly
5. Week 17 onward: 12.5 mg or 15 mg once weekly (maximum dose)

Clinical Trial Results

The SURPASS and SURMOUNT clinical trial programs produced some of the most impressive results ever seen in diabetes and obesity research. These large-scale, randomized controlled trials demonstrated that tirzepatide outperformed existing therapies across multiple endpoints.

SURPASS Trials (Type 2 Diabetes)

• SURPASS-1: Tirzepatide monotherapy reduced HbA1c by up to 2.07% and body weight by up to 9.5 kg (about 21 lbs) at 40 weeks.
• SURPASS-2: Tirzepatide outperformed semaglutide 1 mg, achieving greater HbA1c reduction (−2.46% vs −1.86%) and weight loss (−12.4 kg vs −6.2 kg).
• SURPASS-3: Tirzepatide was superior to insulin degludec in HbA1c reduction and weight loss.
• SURPASS-4: Compared to insulin glargine, tirzepatide showed superior glycemic control with additional cardiovascular safety data.

SURMOUNT Trials (Obesity/Overweight)

The SURMOUNT-1 trial enrolled adults with obesity or overweight (BMI ≥ 30, or ≥ 27 with a weight-related comorbidity) without diabetes. At the highest dose (15 mg), participants lost an average of 22.5% of their body weight over 72 weeks—roughly 52 pounds for someone starting at 230 pounds. Over one-third of participants on the 15 mg dose lost more than 25% of their body weight.

The weight loss observed in SURMOUNT-1 approaches what was previously achievable only through bariatric surgery, marking a paradigm shift in obesity treatment.

Common Side Effects

Like all GLP-1 receptor agonists, Mounjaro's most common side effects are gastrointestinal. These tend to be most pronounced during dose escalation and typically improve over time as the body adjusts.

• Nausea (most common, reported in up to 24% of patients)
• Diarrhea
• Vomiting
• Constipation
• Decreased appetite
• Abdominal pain or discomfort
• Injection site reactions (redness, itching, or swelling)

Serious but Rare Side Effects

• Pancreatitis: Seek immediate medical attention if you experience severe, persistent abdominal pain.
• Gallbladder problems: Rapid weight loss can increase the risk of gallstones.
• Hypoglycemia: More likely when combined with insulin or sulfonylureas.
• Thyroid C-cell tumors: A boxed warning based on animal studies; relevance to humans is uncertain. Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2.
• Allergic reactions: Rare but possible; symptoms include swelling of the face, lips, or throat.

Who Should Not Take Mounjaro?

• Individuals with a personal or family history of medullary thyroid carcinoma (MTC)
• Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Anyone with a known allergy to tirzepatide or any of its inactive ingredients
• Those with a history of severe gastrointestinal disease should use caution and consult their provider

Tips for Starting Mounjaro

• Eat smaller, more frequent meals to reduce nausea.
• Stay hydrated—drink plenty of water throughout the day.
• Avoid high-fat and greasy foods, especially during the first few weeks.
• Inject on the same day each week, but you can change the day if needed (as long as doses are at least 3 days apart).
• Store pens in the refrigerator; do not freeze. An unused pen can be kept at room temperature (up to 86°F / 30°C) for up to 21 days.
• Track your progress and side effects using a companion app to share with your healthcare provider.

The Bottom Line

Mounjaro represents a significant leap forward in the treatment of type 2 diabetes and, increasingly, obesity. Its dual GLP-1/GIP mechanism delivers superior glycemic control and weight loss compared to GLP-1-only medications. While side effects—particularly GI symptoms—are common during dose escalation, they are generally manageable and tend to diminish over time. If you are considering Mounjaro, talk to your healthcare provider about whether it is the right fit for your health goals.

Sources

• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.
• Mounjaro (tirzepatide) Prescribing Information. Eli Lilly.